Regression From Pre-Diabetes to Normal Glucose Regulation in the Diabetes Prevention Program
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Participants in the Diabetes Prevention Program (DPP) randomized to intensive lifestyle modification (ILS) or metformin had a significantly reduced incidence of diabetes compared with those randomized to placebo, yet most were still at risk because they had pre-diabetes. We explored the effect of baseline characteristics, weight change, ILS, and metformin on regression from pre-diabetes to the lowest-risk state of normal glucose regulation (NGR) defined by American Diabetes Association criteria. RESEARCH DESIGN AND METHODS: The DPP was a prospective randomized trial. Cox proportional hazards modeling was used to identify predictors of regression from pre-diabetes to NGR over 3 years of follow-up. RESULTS: Lower baseline fasting (hazard ratio 1.52, P < 0.01) and 2-h (1.24, P < 0.01) glucose predicted regression to NGR, as did younger age (1.07, P < 0.01) and greater insulin secretion (1.09, P = 0.04). ILS (2.05, P < 0.01) and weight loss (1.34, P < 0.01) had significant and independent effects on regression. A nonsignificant trend for regression was also observed for metformin (1.25, P = 0.06), male sex (1.17, P = 0.08), and insulin sensitivity (1.07, P = 0.09). In those entering the study with both impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), male sex and insulin sensitivity predicted regression to isolated IFG, whereas ILS, metformin, female sex, and greater insulin secretion predicted regression to isolated IGT. CONCLUSIONS: Insulin secretion, and other biologic processes retained with younger age, are key in restoring NGR in people with pre-diabetes. However, NGR may also be attained through weight loss and additional aspects of ILS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the Diabetes Prevention Program (DPP), greater baseline β-cell function and insulin sensitivity contributed independently to the restoration of NGT following lifestyle changes ( 65 , 66 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [66]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“ILS and metformin both have been shown to be effective strategies for diabetes prevention, but in the DPP only ILS restored NGR significantly more frequently than did placebo (2).”
BackgroundTuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 3×
“A number of clinical trials have demonstrated the effectiveness of lifestyle and/or drug therapy at preventing diabetes in people with pre-diabetes (2; 4-9), but none have examined the effectiveness of an intervention on returning those with pre-diabetes to NGR.”
BackgroundPrevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866 · cited 1×
“3 he prevalence of type 2 diabetes increased 61% between 1990 and 2001 (1), and by 2005, it affected nearly 21 million Americans (www.”
BackgroundFollow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543 · cited 3×
“A number of clinical trials have demonstrated the effectiveness of lifestyle and/or drug therapy at preventing diabetes in people with pre-diabetes (2; 4-9), but none have examined the effectiveness of an intervention on returning those with pre-diabetes to NGR.”
BackgroundThe Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456 · cited 1×
“Insulin sensitivity and secretion are integrally related and the deterioration of each is felt to be requisite in the development of type 2 diabetes (21).”
BackgroundWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 1×
“Nevertheless, longitudinal data (22) clearly demonstrate the failure of the -cell as the seminal event in this process.”
BackgroundXENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
(2006) · The Lancet · doi:10.1016/s0140-6736(06)69420-8 · Cited by 1,706 · cited 3×
“A number of clinical trials have demonstrated the effectiveness of lifestyle and/or drug therapy at preventing diabetes in people with pre-diabetes (2; 4-9), but none have examined the effectiveness of an intervention on returning those with pre-diabetes to NGR.”
BackgroundEffect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344
Self-citation
Cited by
Items 201–209 of 209
Huang, Z., Han, Y., Hu, H., Cao, C., Liu, D., & Wang, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26647737
Sevilla-González, M. D. R., Merino, J., Moreno-Macías, H., Rojas-Martínez, R., Gómez‐Velasco, D., & Manning, A. K. (2021) · Figshare · doi:10.6084/m9.figshare.14131044
Huang, Z., Han, Y., Hu, H., Cao, C., Liu, D., & Wang, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26647734
Tu, L., Hu, H., Zhou, X., Zhang, H., Liu, X., Yang, D., & He, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25271827
Appetite Regulation and Allostatic Load Across Prediabetes Phenotypes
Malin, S. K., & Heiston, E. M. (2026) · Nutrients · doi:10.3390/nu18010158 · Cited by 1
“…with obesity, it has been described that individuals with IGT often have reduced muscle insulin sensitivity, whereas individuals with IFG have low hepatic insulin sensitivity, such that studies show that IFG, IGT, and IFG + IGT are unique forms of glucose intolerance that promote CVD risk [4–6].”
Strategie di remissione del prediabete
Vazzana, A., Giannatiempo, V., Cubitosi, V., & Dei, A. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01802-5
Zoller, A. R., Athinarayanan, S. J., Tieghem, M. R. V., Adams, R. N., Roberts, C. G. P., Volek, J. S., Phinney, S. D., & McKenzie, A. L. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1839029
“These outcomes compare favorably with long-term outcomes reported for the DPP Lifestyle group, in which approximately 24% of participants progressed to diabetes by 5 years following attenuation of early benefit despite intensive, in-person support (19, 20).”
Lai, F., Pei, L., Xu, C., Xiao, H., Li, Z., Chen, N., Zhou, Y., Liang, S., Zhang, Y., Li, L., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-05059-5
“…secondary outcomes included the percentage of prediabetes remission based on fasting plasma glucose 5.6 mmol/L, and OGTT 2-h plasma glucose 7.8 mmol/L [18], change from baseline in body weight, body mass index (BMI), waist circumference, fasting plasma glucose, 2-h plasma glucose, and HbA1c.”
InfluentialKim, Z., Ha, E. Y., & Park, J. (2026) · Biomolecules · doi:10.3390/biom16101472
“Some individuals progress rapidly to T2DM, whereas others remain metabolically stable or return to normoglycemia, either spontaneously or following intervention [2,4,5].”
Influential
Metadata
- Authors
- Perreault, L., Kahn, S. E., Christophi, C. A., Knowler, W. C., Hamman, R. F., & the Diabetes Prevention Program Research Group
- Affiliations
- University of Colorado Anschutz (US)
- University of Washington (US)
- George Washington University (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Colorado School of Public Health (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-07-08
- Volume
- 32
- Issue
- 9
- Pages
- 1583-1588
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2732165
- OpenAlex
- W2109748090
- Cited by
- 209
- References
- 25
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 19 · 2023: 12 · 2022: 9 · 2021: 16 · 2020: 14 · 2019: 12 · 2018: 15 · 2017: 14 · 2016: 8 · 2015: 11 · 2014: 13 · 2013: 14 · 2012: 9
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- prediabetes, Diabetes Prevention Program, intensive lifestyle intervention, metformin, weight loss, insulin secretion, insulin sensitivity, impaired fasting glucose, impaired glucose tolerance
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Insulin, Life Style, Male, Metformin, Middle Aged, Prediabetic State, Sex Factors, Weight Loss, Multivariate Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.